Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;30(8):597-623.
doi: 10.2174/0113816128291798240201112916.

2,5-Diketopiperazines (DKPs): Promising Scaffolds for Anticancer Agents

Shaimaa S Goher  1   2 , Wessam S Abdrabo  1 , Giri Babu Veerakanellore  3   4 , Bahaa Elgendy  1   3   4
Affiliations
Review

2,5-Diketopiperazines (DKPs): Promising Scaffolds for Anticancer Agents

Shaimaa S Goher et al. Curr Pharm Des. 2024.

Abstract

2,5-Diketopiperazine (2,5-DKP) derivatives represent a family of secondary metabolites widely produced by bacteria, fungi, plants, animals, and marine organisms. Many natural products with DKP scaffolds exhibited various pharmacological activities such as antiviral, antifungal, antibacterial, and antitumor. 2,5-DKPs are recognized as privileged structures in medicinal chemistry, and compounds that incorporate the 2,5-DKP scaffold have been extensively investigated for their anticancer properties. This review is a thorough update on the anti-cancer activity of natural and synthesized 2,5-DKPs from 1997 to 2022. We have explored various aspects of 2,5-DKPs modifications and summarized their structure-activity relationships (SARs) to gain insight into their anticancer activities. We have also highlighted the novel approaches to enhance the specificity and pharmacokinetics of 2,5-DKP-based anticancer agents.

Keywords: 2; 5-DKPs); 5-Diketopiperazines (2; anticancer activities; marine fungus; natural alkaloids; natural products; pharmacological activities..

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Borthwick A.D.; 2,5-Diketopiperazines: Synthesis, reactions, medicinal chemistry, and bioactive natural products. Chem Rev 2012,112(7),3641-3716 - DOI - PubMed
    1. Huang R.; Zhou X.; Xu T.; Yang X.; Liu Y.; Diketopiperazines from marine organisms. Chem Biodivers 2010,7(12),2809-2829 - DOI - PubMed
    1. Martins M.B.; Carvalho I.; Diketopiperazines: Biological activity and synthesis. Tetrahedron 2007,63(40),9923-9932 - DOI
    1. Greve H.; Mohamed I.E.; Pontius A.; Kehraus S.; Gross H.; König G.M.; Fungal metabolites: Structural diversity as incentive for anticancer drug development. Phytochem Rev 2010,9(4),537-545 - DOI
    1. Mahar K.M.; Enslin M.B.; Gress A.; Amrine-Madsen H.; Cooper M.; Single‐ and multiple‐day dosing studies to investigate high‐dose pharmacokinetics of epelsiban and its metabolite, gsk2395448, in healthy female volunteers. Clin Pharmacol Drug Dev 2018,7(1),33-43 - DOI - PubMed

MeSH terms

LinkOut - more resources